Rebecca Saxe’s work addresses the human brain’s capacity for abstract thought and the origins of ‘theory of mind,’ the ability to understand the beliefs, hopes and plans of other people.
Rebecca Saxe
Professor
Massachussetts Institute of Technology
From this contributor
U.S. agency backtracks on broad interpretation of ‘clinical trial’
Autism researchers need no longer worry that their basic research will become entangled in the red tape associated with clinical trials.
U.S. agency backtracks on broad interpretation of ‘clinical trial’
By
Hannah Furfaro
6 February 2018 | 6 min read
1985 paper on the theory of mind
In 1985, Simon Baron-Cohen, Alan Leslie and Uta Frith reported for the first time that children with autism systematically fail the false belief task.
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read